Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome (ticagrelor)
Acute Coronary Syndrome
About this trial
This is an interventional treatment trial for Acute Coronary Syndrome focused on measuring semi-urgent CABG, reanimation, ticagrelor, crushed tablet
Eligibility Criteria
Inclusion Criteria:
- Subject with an acute myocardial infarction with ST elevation
- Subject with an acute myocardial infarction without ST elevation
- Subject with unstable angina (progressive angina during past 2 weeks, negative cardiac markers, Trop T < 0,014μg/l
- First time of taking Brilique
- ≥ 18 years
- Possibility to take a blood sample before administration of Brilique
- Signed Informed Consent, signed by subject or authorized representative, able and willing to provide written informed consent for study participation
Exclusion Criteria:
- Active haemorrhage
- Moderate or severe liver failure with coagulopathy
- Pregnancy and lactation
- A history of an intra cerebral haemorrhage
- Patient is HIV positive and treated with Ritonavir and /or Atazanavir
- Patient treated with vitamin K antagonist or with a new oral anti coagulant
- Hypersensitivity to ticagrelor or any of the excipients
Sites / Locations
- Intensive Care Unit, Ghent University Hospital
Arms of the Study
Arm 1
Other
starting with ticagrelor
Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations. When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations.